Table Graph
      published meta-analysis   sensitivity analysis   studies

Covishield (Oxford/AZ formulation) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias adverse eventsdetailed resultsKulkarni, 2021 1.31 [0.98; 1.76] 1.31[0.98; 1.76]Kulkarni, 202110%1,500NAnot evaluable intracranial hemorrhage detailed resultsKulkarni, 2021 0.25 [0.00; 12.61] 0.25[0.00; 12.61]Kulkarni, 202110%1,500NAnot evaluable ischemic strokedetailed resultsKulkarni, 2021 0.25 [0.00; 12.61] 0.25[0.00; 12.61]Kulkarni, 202110%1,500NAnot evaluable Myocardial infarction detailed resultsKulkarni, 2021 0.25 [0.00; 12.61] 0.25[0.00; 12.61]Kulkarni, 202110%1,500NAnot evaluable pulmonary embolismdetailed resultsKulkarni, 2021 0.25 [0.00; 12.61] 0.25[0.00; 12.61]Kulkarni, 202110%1,500NAnot evaluable serious adverse events (SAE), anydetailed resultsKulkarni, 2021 1.89 [0.43; 8.29] 1.89[0.43; 8.29]Kulkarni, 202110%1,500NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-06-02 20:39 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 1284 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons